Synthesis and Evaluation of New 1, 4-Dihydropyridine Derivatives as Potential Breast Cancer Therapeutics: HER2 Inhibition Efficacy Study Using MCF-7 and SK-BR-3 Cells and Molecular Docking
Abstract
The derivatives of 1,4-Dihydropyridine compound have gained significant interest for their potential-anticancer properties particularly in targeting breast-cancer. The study aimed to synthesize and evaluate the anticancer activity of four novel 1,4-dihydropyridine derivatives (5a–d) against breast cancer cell lines MCF-7 and SK-BR-3. The derivatives were synthesized via the reaction of N-(4-nitrophenyl)-3-oxobutanamide with substituted benzaldehyde and ammonium acetate. Cytotoxic activity was assessed using MCF-7 and SK-BR-3 cells, and IC₅₀ values were determined. Molecular docking was performed to evaluate the binding affinity of the compounds to the HER2 receptor. Structural characterization was conducted using FT-IR, ¹H-NMR, ¹³C-NMR, and mass spectrometry. All four derivatives (5a–d) demonstrated higher inhibition rates in SK-BR-3 cells (72%, 83%, 89%, and 85%, respectively) compared to MCF-7 cells (51%, 54%, 58%, and 55%) at a concentration of 100 μg. Compound 5c exhibited the highest cytotoxicity, with the lowest IC₅₀ value (18.5 μg/mL) against SK-BR-3 cells, followed by 5b and 5d, while 5a showed the weakest effect. Molecular docking results supported the potential of these compounds as HER2-targeted agents. The synthesized 1,4-dihydropyridine derivatives, particularly compound 5c, demonstrated promising anticancer activity, especially against HER2-positive SK-BR-3 cells.